Open Orphan #ORPH – Contract extension with Carna Biosciences February 1, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract renewal with Carna Biosciences, Inc. (“Carna”), extending its integrated drug development consultancy services with Venn Life Sciences (“Venn”), part of Open Orphan plc. Carna Biosciences is a clinical-stage biopharmaceutical company which focuses on the discovery and development of innovative therapies to treat serious unmet…

Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4 September 30, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan Plc, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical studies is pleased to announce its interim results for the six months ended 30 June 2020. The interim results include the first six months of hVIVO group (“hVIVO”) following its acquisition by Open Orphan Plc on the 17 January 2020. Operational Highlights: · Completed the acquisition of hVIVO…

Open Orphan #ORPH – New Contract Win with Carna Bioscience August 4, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce the signing of a new contract with Carna Bioscience ( www.carnabio.com ) for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for Venn Life Sciences (“Venn”) over the next twelve months. The contract sees the…

Open Orphan (ORPH) Contract signed with Carna Bioscience November 18, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a contract with Carna Bioscience (“Carna”) (www.carnabio.com) for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next twelve months. Carna is a Japanese company specialising in kinase biology, developing innovative treatments against cancer and immune disorders. This contract sees Venn Life Sciences (“Venn”), part…

Open Orphan #ORPH – Contract extension with Carna Biosciences February 1, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4 September 30, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan #ORPH – New Contract Win with Carna Bioscience August 4, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan (ORPH) Contract signed with Carna Bioscience November 18, 2019 – Posted in: Open Orphan (ORPH)

Address

Contact

Social

LEGAL